Evelo (EVLO) drops 10.25% on Strong Volume September 14

Equities Staff  |

Evelo Biosciences Inc (NASDAQ: EVLO) shares dropped 10.25%, or $0.775 per share, to close Tuesday at $6.79. After opening the day at $7.66, shares of Evelo fluctuated between $7.94 and $6.67. 509,883 shares traded hands an increase from their 30 day average of 158,571. Tuesday's activity brought Evelo’s market cap to $362,307,411.

About Evelo Biosciences Inc

Evelo Biosciences is a clinical stage biotechnology company developing orally delivered product candidates that are designed to act on the small intestinal axis, SINTAX™, with systemic therapeutic effects. SINTAX plays a central role in governing the immune, metabolic, and neurological systems. The Company's first product candidates are pharmaceutical preparations of single strains of microbes selected for the potential to offer defined pharmacological properties. Evelo's therapies have the potential to be effective, safe, and affordable medicines to improve the lives of people with inflammatory diseases and cancer.

Visit Evelo Biosciences Inc’s profile for more information.

About The Nasdaq Stock Market

The Nasdaq Stock Market is a global leader in trading data and services, and equities and options listing. Nasdaq is the world's leading exchange for options volume and is home to the five largest US companies - Apple, Microsoft, Amazon, Alphabet and Facebook.

To get more information on Evelo Biosciences Inc and to follow the company’s latest updates, you can visit the company’s profile page here: Evelo Biosciences Inc’s Profile. For more news on the financial markets be sure to visit Equities News. Also, don’t forget to sign-up for the Daily Fix to receive the best stories to your inbox 5 days a week.

Sources: Chart is provided by TradingView based on 15-minute-delayed prices. All other data is provided by IEX Cloud as of 8:05 pm ET on the day of publication.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer


Trending Articles

President Biden Hosting Leaders From India, Japan, Australia Friday in First 'Quad' Summit
Some Chinese Banks Stop Offering New Credit to Property Developers Amid Evergrande Scare
Iowa Senator Chuck Grassley Seeks Eighth Term of Office
House Select Committee Subpoenas Four Trump Allies in US Capitol Riot Probe
CDC Endorses COVID-19 Vaccine Booster Shots for Millions of Older and Vulnerable Individuals
Semiconductor Shortage To Cost Global Auto Industry $210 Billion in Revenue in 2021
US Olympic Athletes Must Have COVID-19 Vaccination for Beijing Winter Games
FAA Urges Airlines To Take Stronger Action With Unruly, Disruptive Passengers



Market Movers

Sponsored Financial Content